Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Drug Pipeline

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. maintains a substantial clinical portfolio, with 39 registered trials since 2008, of which 32 are currently active. These active trials span from Phase 1 through Phase 4, indicating a mix of early- and late-stage development programs. The portfolio encompasses four therapeutic areas, with a significant concentration in Metabolic diseases, which accounts for 50% of active programs, or 16 trials. Within Metabolic diseases, the leading indications are Obesity, with 9 active trials including 3 in Phase 3, and Type 2 Diabetes, with 7 active trials including 4 in Phase 3. Oncology represents the second-largest area of focus, with 11 active trials. Immunology and Renal indications are also represented, with 2 and 1 active trials, respectively. The weighting toward Phase 3 trials in key Metabolic indications suggests a potential for near-term clinical catalysts.